Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.

Avacta announces two key clinical updates to its faridoxorubicin program Cardiac dosing limit removed and path forward to dose selection identified

The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026

Avacta Group plc reported strong operational progress in 2025, having raised £22.5m in equity to support its research and development programmes. The company ended the year with unaudited cash reserves

Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence

Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society

Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets